Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + Veledimex in Advanced Breast Cancer
NCT02423902Phase 2Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ad-rts-hil-12 in breast cancer, sponsored by Alaunos Therapeutics. Started Jul 2015; status: terminated.
02
Drugs
ad-rts-hil-12
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02423902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423902.